D-0174-2021 Class II Terminated

Recalled by Morton Grove Pharmaceuticals, Inc. — Morton Grove, IL

FDA drug recall D-0174-2021 was initiated by Morton Grove Pharmaceuticals, Inc. on Dec 9, 2020 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specification: OOS for the following - unknown degradant/impurity, 4-chorobenzophenone, and for total impurities. The recall status is terminated (terminated Sep 24, 2022). Affected quantity: 127,392 bottles.

Recall details

Product Type
Drugs
Report Date
Dec 30, 2020
Initiation Date
Dec 9, 2020
Termination Date
Sep 24, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
127,392 bottles

Product description

Hydroxyzine Hydrochloride Oral Solution, USP (Syrup), 10 mg/5 mL, packaged in a) 4 fl oz (118 mL) bottle, NDC 60432-150-04, b) 1 pint (473 mL), NDC 60432-150-16, Rx Only, Manufactured By: Morton Grove Pharmaceuticals, Inc., Morton Grove, IL 60053

Reason for recall

Failed Impurities/Degradation Specification: OOS for the following - unknown degradant/impurity, 4-chorobenzophenone, and for total impurities.

Distribution pattern

Nationwide USA and Puerto Rico

Code information

Lot#: a) UU1328, Exp 10/21; b) UU1207, Exp 07/21; UU1326, Exp 09/21; UU1327, Exp 10/21.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0174-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0174-2021. Report a data issue: hello@regdatalab.com.